Overview

Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC

Status:
RECRUITING
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
This study will explore the efficacy and safety of benmelstobart combined with radiochemotherapy compared to radiochemotherapy alone as neoadjuvant treatment for esophageal squamous cell carcinoma. It will also compare the effectiveness and safety of low-dose radiotherapy versus standard-dose radiotherapy in neoadjuvant regimens that include benmelstobart with concurrent radiochemotherapy. This research may provide more treatment options for patients with esophageal squamous cell carcinoma.
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Zhongshan Hospital
Treatments:
Carboplatin
Paclitaxel
Radiotherapy